ALKS Stock Analysis: Alkermes | NASDAQ

Antipsychotics, Addiction Treatment, Neuroscience, Drug Delivery

Total Rating 54

Safety 28

Buy Signal 0.15

Drug Manufacturers - Specialty & Generic
Industry Rotation: +2.5

Market Cap: 7.73B
Avg Turnover: 60.2M

Risk 3d forecast

Volatility34.5%

VaR 5^th Pctl5.55%

VaR vs Median-2.43%

Reward TTM

Sharpe Ratio1.30

Rel. Str. IBD87.8

Rel. Str. Peer Group59.8

Character TTM

Beta0.825

Beta Downside1.121

Hurst Exponent0.562

Drawdowns 3y

Max DD29.33%

CAGR/Max DD0.52

CAGR/Mean DD1.11

EPS (Earnings per Share)

EPS CAGR: 13.56%
EPS Trend: 45.0%

Last SUE: 2.98
Qual. Beats: 2

Revenue

Rev. CAGR: -1.56%
Rev. Trend: -28.4%

Last SUE: 1.71
Qual. Beats: 2

Warnings

P/E Ratio 121.3

Beneish M-Score Likely Earnings Manipulation

Below Avwap Earnings

Tailwinds

No distinct edge detected

Seasonality 11.6 years of data

Jan +4.2% 22

Feb -0.6% 17

Mar +0.1% 7

Apr -4.0% 31

May +1.4% 18

Jun +6.0% 8

Jul -3.4% 11

Aug -3.1% 13

Sep -1.2% 17

Oct -2.0% 18

Nov +5.7% 13

Dec +1.1% 16

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: ALKS Alkermes

Alkermes plc is an Ireland-based biopharmaceutical company headquartered in Dublin that develops and commercializes treatments for central nervous system (CNS) disorders and addiction. The companys commercial portfolio focuses on schizophrenia, bipolar I disorder, alcohol and opioid dependence, and narcolepsy-related conditions, with marketed products including ARISTADA, ARISTADA INITIO, VIVITROL, LYBALVI, and LUMRYZ.

In addition to its proprietary products, Alkermes maintains a pipeline of clinical and preclinical candidates targeting neurological disorders and licenses its proprietary drug delivery technology platforms to third parties for use in their own development and manufacturing efforts. The company has long-standing collaboration agreements with Janssen Pharmaceutica and operates primarily in the United States, Ireland, and international markets.

As a mid-cap biotechnology company, Alkermes operates within a sector that depends heavily on patent protection, FDA regulatory approvals, and sustained R&D investment. Its dual business model-combining proprietary drug development with technology platform licensing-is a common approach in specialty CNS-focused pharma, allowing companies to diversify revenue streams while concentrating expertise in a defined therapeutic area. Ireland is a frequent corporate domicile for pharmaceutical firms due to the countrys established life sciences ecosystem and favorable corporate tax framework.

Headlines to Watch Out For

LUMRYZ launch drives revenue growth in narcolepsy franchise
Janssen royalty revenue from Invega underpins operating margins
ARISTADA and LYBALVI sales offset VIVITROL generic pressure

Piotroski VR-10 (Strict) 2.5

Net Income: 66.1m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA -16.25 > 1.0
NWC/Revenue: 51.62% < 20% (prev 75.02%; Δ -23.41% < -1%)
CFO/TA 0.06 > 3% & CFO 251.2m > Net Income 66.1m
Net Debt (987.3m) to EBITDA (218.0m): 4.53 < 3
Current Ratio: 2.30 > 1.5 & < 3
Outstanding Shares: last quarter (166.6m) vs 12m ago -1.04% < -2%
Gross Margin: 84.56% > 18% (prev 85.13%; Δ -0.57% > 0.5%)
Asset Turnover: 50.19% > 50% (prev 66.82%; Δ -16.63% > 0%)
Interest Coverage Ratio: 2.65 > 6 (EBIT TTM 156.4m / Interest Expense TTM 59.1m)

Altman Z'' 1.74

A: 0.20 (Total Current Assets 1.52b - Total Current Liabilities 662.1m) / Total Assets 4.39b
B: -0.18 (Retained Earnings -800.8m / Total Assets 4.39b)
C: 0.05 (EBIT TTM 156.4m / Avg Total Assets 3.32b)
D: 0.70 (Book Value of Equity 1.81b / Total Liabilities 2.58b)
Altman-Z'' = 1.74 = BBB

Beneish M -0.78

DSRI: 1.16 (Receivables 456.5m/354.9m, Revenue 1.67b/1.51b)
GMI: 1.01 (GM 85.13% / 84.56%)
AQI: 4.44 (AQ_t 0.59 / AQ_t-1 0.13)
SGI: 1.11 (Revenue 1.67b / 1.51b)
TATA: -0.04 (NI 66.1m - CFO 251.2m) / TA 4.39b)
Beneish M = -0.78 (Cap -4..+1) = D

What is the price of ALKS shares?

As of September 11, 2026, the stock is trading at USD 45.40 with a total of 1,366,568 shares traded. Over the past week, the price has changed by -3.81%, over one month by -8.10%, over three months by +2.51% and over the past year by +63.02%.

Current recommended Stop Loss: 41.60 (which is 8.4% or 2.5 ATR below the current price).

Is ALKS a buy, sell or hold?

Alkermes has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy ALKS.

StrongBuy: 8
Buy: 1
Hold: 6
Sell: 0
StrongSell: 0

What are the forecasts/targets for the ALKS price?

Analysts Target Price	56	23.3%

Alkermes (ALKS) - Fundamental Data Overview as of 07 September 2026

Market Cap USD = 7.73b (7.73b USD * 1.0 USD.USD)
P/E Trailing = 121.3158
P/E Forward = 133.3333
P/S = 4.6376
P/B = 4.3477
P/EG = 1.9605
Revenue TTM = 1.67b USD
EBIT TTM = 156.4m USD
EBITDA TTM = 218.0m USD
Long Term Debt = 1.48b USD (from longTermDebt, two quarters ago)
Short Term Debt = 34.0m USD (from shortTermDebt, last quarter)
Debt = 1.64b USD (from shortLongTermDebtTotal, last quarter) + Leases 71.3m
Net Debt = 987.3m USD (calculated: Debt 1.64b - CCE 656.6m)
Enterprise Value = 8.72b USD (7.73b + Debt 1.64b - CCE 656.6m)
Interest Coverage Ratio = 2.65 (Ebit TTM 156.4m / Interest Expense TTM 59.1m)
EV/FCF = 39.35x (Enterprise Value 8.72b / FCF TTM 221.7m)
FCF Yield = 2.54% (FCF TTM 221.7m / Enterprise Value 8.72b)
FCF Margin = 13.29% (FCF TTM 221.7m / Revenue TTM 1.67b)
Net Margin = 3.97% (Net Income TTM 66.1m / Revenue TTM 1.67b)
Gross Margin = 84.56% ((Revenue TTM 1.67b - Cost of Revenue TTM 257.5m) / Revenue TTM)
Gross Margin QoQ = 80.22% (prev 84.33%)
Tobins Q-Ratio = 1.99 (Enterprise Value 8.72b / Total Assets 4.39b)
Interest Expense / Debt = 3.59% (Interest Expense 59.1m / Debt 1.64b)
Taxrate = 32.06% (31.2m / 97.3m)
NOPAT = 106.3m (EBIT 156.4m * (1 - 32.06%))
Current Ratio = 2.30 (Total Current Assets 1.52b / Total Current Liabilities 662.1m)
Debt / Equity = 0.91 (Debt 1.64b / totalStockholderEquity, last quarter 1.81b)
Debt / EBITDA = 4.53 (Net Debt 987.3m / EBITDA 218.0m)
Debt / FCF = 4.45 (Net Debt 987.3m / FCF TTM 221.7m)
Total Stockholder Equity = 1.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.99% (Net Income 66.1m / Total Assets 4.39b)
RoE = 3.72% (Net Income TTM 66.1m / Total Stockholder Equity 1.78b)
RoCE = 4.79% (EBIT 156.4m / Capital Employed (Equity 1.78b + L.T.Debt 1.48b))
RoIC = 2.89% (NOPAT 106.3m / Invested Capital 3.68b)
WACC = 7.75% (E(7.73b)/V(9.38b) * Re(8.88%) + D(1.64b)/V(9.38b) * Rd(3.59%) * (1-Tc(0.32)))
Discount Rate = 8.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -65.80 | Cagr: -1.65%
[DCF] Terminal Value 73.10% ; FCFF base≈324.9m ; Y1≈284.9m ; Y5≈230.2m
[DCF] Fair Price = 16.14 (EV 3.70b - Net Debt 987.3m = Equity 2.71b / Shares 167.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 44.97 | EPS CAGR: 13.56% | SUE: 2.98 | # QB: 2
Revenue Correlation: -28.40 | Revenue CAGR: -1.56% | SUE: 1.71 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.25 | Chg30d=-31.57% | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=1.27 | Chg30d=+29.57% | Revisions=+0% | GrowthEPS=-39.2% | GrowthRev=+23.6%
EPS next Year (2027-12-31): EPS=1.83 | Chg30d=+17.46% | Revisions=+0% | GrowthEPS=+43.4% | GrowthRev=+6.6%
[Analyst] Revisions Ratio: -12% (up=2, down=3)